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1. Introduction
Amyloidosis is uncommon, with age-adjusted incidences of between 6.1 and 10.5 per million
person-years,[1] and an estimated 1275 to 3200 new cases occurring annually in the United
States.[1, 2] The contemporary understanding of amyloidosis points to a group of complex sys‐
temic disorders involving the extracellular deposition of misfolded proteinaceous material in
many organs, most commonly the kidneys, heart, liver, central and peripheral nervous sys‐
tems.[2-4] The normal function of tissues is altered, and end-organ dysfunction usually ensues.
Cardiac amyloidosis can be isolated to the heart, but it often coexists with disease elsewhere in
the body.[4, 5] Cardiac manifestations may predominate the clinical presentation or may be
subclinical and detected on routine investigation of a patient presenting with non-cardiac com‐
plaints.[5] The presence and relative prominence of cardiac involvement in the clinical picture
is dependent on the type of amyloidosis and severity of amyloid infiltration in the tissue.[5]
2. Classification of amyloidosis
Amyloidosis refers to a group of unrelated diseases involving the extracellular deposition of
proteinaceous material that demonstrates apple-green birefringence under polarized light
on staining with Congo red.[5] In all forms of amyloidosis, abnormal and unstable protein is
produced in response to a variety of stimuli and precipitates as amyloid in the extracellular
matrix.[2, 3] The contemporary classification of amyloidosis is primarily based on the bio‐
chemistry of the disease process from the precursor amyloid proteins, and comprises several
major subgroups. Table 1 describes the typical characteristics of each type of amyloidosis.
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Type of
amyloidosis
Precursor
protein
Spectrum of
organ
involvement
Frequency of
cardiac
involvement
Median
survival,
months
Diagnostic
testing
Treatment
Immunoglobu‐
lin amyloidosis
(AL)
Immunoglobulin
light chain
Heart, kidneys, liv‐
er, peripheral/
autonomic nervous
systems, soft tissue,
gastrointestinal
system
Up to 50% have
clinical cardiac in‐
volvement
13 (4 months
if heart failure
present at di‐
agnosis)
SPEP, UPEP, bone
marrow biopsy
tissue analysis re‐
vealing plasma
cell dyscrasia, κ
and λ light chain
antiserum stain‐
ing
Anti-plasma cell
chemotherapy,
autologous stem
cell replacement,
sequential heart
and stem cell
transplant
Familial amyloi‐
dosis (ATTR)
Mutant transthyre‐
tin
Peripheral/auto‐
nomic nervous sys‐
tems, heart
Variable, depend‐
ing on exact muta‐
tion
70 ATTR antiserum
staining, serum
TTR isoelectric fo‐
cusing, restriction
fragment length
polymorphism
analysis
Liver transplanta‐
tion, combined
liver and heart
transplantation in
certain cases, new
pharmacological
strategies to stabi‐
lize TTR
Senile systemic
amyloidosis
Wild-type trans‐
thyretin
Heart (predomi‐
nant, usually atrial)
Common 75 ATTR antiserum
staining
Supportive, new
pharmacological
strategies to stabi‐
lize TTR
Reactive amyloi‐
dosis (SAA)
Serum amyloid A Kidney, heart Uncommon, <10% 24.5 Target organ bi‐
opsy specimen
analysis, AA anti‐
serum staining
Treat the underly‐
ing inflammatory
process
Hemodialysis-as‐
sociated amyloi‐
dosis
β2-microglobulin Musculoskeletal
system, rare in
heart
Unknown, asymp‐
tomatic
Unclear clini‐
cal signifi‐
cance
Synovial and
bone biopsy
specimen analy‐
sis, β2-microglo‐
bulin antiserum,
serum β2-micro‐
globulin concen‐
tration
Renal transplanta‐
tion
Isolated atrial
amyloidosis
Atrial natriuretic
peptide
Heart Limited to heart Unclear clini‐
cal signifi‐
cance
Atrial natriuretic
peptide antise‐
rum staining
None required
Table 1. Types of amyloidosis affecting the heart.
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2.1. Immunoglobulin light chain amyloidosis (AL)
AL amyloidosis is a monoclonal plasma cell disorder in which the precursor protein is an
immunoglobulin light chain or light chain fragment. It may occur as a primary disease or in
association with multiple myeloma or other plasma cell dyscrasias.[3, 6], 7] The median num‐
ber of clonal plasma cells in AL amyloidosis is between 5% and 10%.[2] The extent of clonal
plasma cell marrow infiltration is an important prognositic indicator, presumably because it
reflects the degree of pathogenic light chain synthesis.[8] In primary amyloidosis, there is 2:1
preponderance for λ over κ light chain synthesis.[9] While in itself uncommon, with an inci‐
dence of 8.9 per million,[1] AL amyloidosis is the commonest type of amyloidosis, account‐
ing for about 85% of all newly diagnosed cases.[3, 10] The clinical picture of AL amyloidosis
is the most varied, since it commonly affects a large number of organ systems including the
heart, kidney, liver, peripheral and autonomic nervous systems, soft tissue and gastrointesti‐
nal systems.[3, 5] The heart is affected in over 50% of cases,[11] and symptomatic cardiac in‐
volvement portends a worse prognosis.[11, 12] Conversely, involvement limited to the heart
constitutes <5% of patients with AL amyloidosis.[11] Cardiac involvement with resultant
heart failure or arrhythmia accounts for >50% of the mortality in patients with AL amyloido‐
sis.[12] Furthermore, thromboembolism also contributes significantly to morbidity and mor‐
tality. Intracardiac thrombosis was found in 51% and 35% of subjects with AL amyloidosis
in the Mayo amyloid autopsy study and in a group of patients undergoing follow up echo‐
cardiographic imaging respectively.[13, 14]
2.2. Familial amyloidosis (ATTR)
Familial amyloidosis is a hereditary autosomal dominant disorder involving amyloidogenic
mutations in most commonly the transthyretin gene.[15] The age of onset of familial amyloi‐
dosis appears to vary with ethnicity. Interestingly, about 10% of gene carriers remain
asymptomatic (although the disease manifestation can be age dependent with variable pene‐
trance),[16-18] suggesting that the pathogenesis of these diseases may involve other genetic
or environmental factors. Familial amyloidosis usually affects the peripheral and autonomic
nervous systems and the heart.[5] While usually more slowly progressive than AL amyloi‐
dosis, the familial type may also cause clinically significant heart failure. Significant cardiac
disease is associated with mutations at positions 30, 60 and 84 of the transthyretin gene.[17]
A mutation involving isoleucine at position 122 which involves solely the heart has been de‐
scribed in elderly African-American persons.[19, 20] This form of amyloid is probably un‐
derdiagnosed since nearly 4% of newborn African Americans harbor this mutation.[19] The
TranstHyretin Amyloidosis Outcome Survey (THAOS) registry is a global observational
survey set up with the aim of furthering our understanding of hereditary amyloidosis.
2.3. Senile systemic amyloidosis
Senile systemic amyloidosis is primarily a disease of the elderly, most commonly affecting
men over the age of 70. It accounts for approximately 25% of patients over 80 years with
amyloidosis.[21, 22] It is caused by wild-type transthyretin.[5, 21] Cardiac, particularly at‐
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rial, involvement is common,[23, 24] and may be associated with clinically significant heart
failure, atrial fibrillation and conduction abnormalities.[25, 26]
2.4. Reactive amyloidosis (SAA)
Reactive amyloidosis is characterized by the deposition of serum amyloid A protein (SAA),
an acute phase reactant produced in response to chronic inflammatory processes such as
chronic infections, rheumatologic disease and familial periodic fever syndromes.[27, 29]
With efficacious treatment of chronic infections in patients in the developed world, the inci‐
dence of reactive amyloidosis has fallen.[29] The kidney is commonly involved, [5] and car‐
diac involvement, if present, is rarely clinically significant.[30, 31]
2.5. Hemodialysis-associated amyloidosis (Aβ2M)
Hemodialysis-associated amyloidosis occurs in chronic renal failure patients undergoing he‐
modialysis.[12] β2-microglobulin is the precursor protein.[32, 33] Musculoskeletal involve‐
ment is common, and the clinical effect from cardiac deposition is minimal and typically
clinically insignificant.[34, 35]
2.6. Isolated atrial amyloidosis (AANF)
Isolated atrial amyloidosis is predominantly seen in those >80 years and in females,[23] but
also occurs in younger patients with valvular abnormalities or chronic atrial fibrillation.
[36-38] The precursor protein is atrial natriuretic peptide.[39-41] Involvement is usually lim‐
ited to the subendocardial region of the heart, and its clinical significance is unclear.[42]
3. Pathophysiology of cardiac amyloidosis
In cardiac amyloidosis, the clinical presentation is typically heart failure with initially pre‐
served ejection fraction and restrictive diastolic physiology. This has led to its classification
as a “restrictive” cardiomyopathy.[3, 5, 9, 43] This is defined by a high filling pressure that
can lead classically to heart failure with preserved ejection fraction. Cardiac contractile func‐
tion and electrical conduction can be impaired with amyloid infiltration.[9] At a cellular lev‐
el, amyloid infiltration results in abnormal cellular metabolism, calcium transport and
receptor regulation. [3] Adrenergic input is disrupted and the neurohormonal milieu is al‐
tered in cardiac amyloidosis.[44] Amyloid deposition induces oxidant stress[45] and modu‐
lates interstitial matrix composition and tissue remodeling,[46] leading to further depression
of myocyte contractility. Furthermore, there is evidence of a direct toxic role of the monoclo‐
nal light chain extracted from the urine of AL patients on myocardial diastolic function in
the mouse hearts; infusion of the monoclonal light chain caused a significant elevation in the
LV end diastolic pressure in this animal model.[47] Involvement of the coronary microvas‐
culature may also result in coronary flow abnormalities; this is seen in 90% of patients with
AL amyloidosis.[48] This global involvement leads to diffuse ischemia and microinfarction,
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further compromising cardiac contractility.[49] The resultant perivascular amyloid infiltra‐
tion commonly involves the conduction system, leading to conduction abnormalities.[50, 51]
4. Clinical presentation – When should physicians suspect amyloidosis?
Depending on the spectrum of organ involvement, a patient can present with a multitude of
symptoms and signs which are often nonspecific and variable, especially in the early stages
of disease.[12] This is particularly so in AL amyloidosis, in which many systems can be af‐
fected. Common constitutional complaints include weakness, fatigue, peripheral edema and
weight loss.[9] Hepatomegaly is common and results from either direct hepatic infiltration or
congestion secondary to cardiac failure.[52, 53] Renal involvement may cause profound pro‐
teinuria and the nephrotic syndrome.[5, 9] Easy bruising and periorbital purpura results
from clotting factor deficiencies and fragile venules; the latter is virtually pathognomonic of
the AL type disease.[54, 55] Soft tissue involvement may result in carpal tunnel syndrome[5,
9] and macroglossia,[56] while peripheral and/or autonomic neuropathy may be the hall‐
mark of neurological involvement.[5, 9, 12] The presence of complaints involving multiple
organ systems without any other known cause should trigger a search for multisystem dis‐
ease, one of which being amyloidosis. Early diagnosis improves outcomes, given the irrever‐
sible damage caused by amyloidosis and that patients with advanced disease are often not
candidates for definitive treatment options (some of which may be curative),[43] but this re‐
quires a high index of suspicion and a systematic algorithm for evaluation.[4, 9]
Cardiac findings are predominantly due to diastolic dysfunction, also known as heart failure
with preserved ejection fraction.[3, 5, 9] The initial presentation is often that of progressive
exertional dyspnea followed by worsening heart failure, pulmonary congestion, pleural ef‐
fusions, edema, and ascites.[11] Valvular insufficiency or stenosis due to endocardial in‐
volvement may result in a murmur,[9, 43, 57] and atrial fibrillation is common, although all
manner of arrhythmias have been reported.[57, 58] Coronary flow abnormalities due to mi‐
crovascular involvement may present as angina chest pain;[59] rarely, this may be the only
presenting complaint.[59-63] Patients may have syncope and lightheadedness, particularly
postural, caused by autonomic dysfunction and arrhythmias in the face of declining cardiac
functional reserve.[64] The heart should be screened in all patients with known or suspected
amyloidosis even in the absence of cardiac symptoms, as involvement of the heart portends
a poor prognosis and affects treatment strategies.[3]
5. Diagnosis and evaluation of cardiac amyloidosis
Histologic examination remains the definitive diagnostic modality in cardiac amyloidosis.[9,
65] While not definitive, certain non-invasive imaging and laboratory findings may guide
further diagnostic testing and management and assess the severity of the disease for prog‐
nostic purposes.[9, 43] Often, the diagnosis of cardiac amyloidosis and perhaps the type of
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amyloidosis can be reasonably ascertained by employing one or more non-invasive imaging
and laboratory modalities.
5.1. Echocardiography
Echocardiography remains the most widely utilized noninvasive modality in the diagnosis
of cardiac amyloidosis, in part because of its widespread availability and relatively low cost.
[5, 66] In cases with characteristic echocardiographic findings, signs and symptoms of heart
failure, and a positive biopsy of another organ, cardiac involvement is almost certain. How‐
ever, echocardiography cannot determine the type of amyloidosis and in some patients with
early disease the findings may be subtle.[43]
Echocardiography may show mild diastolic dysfunction [9] as the only clue in early amyloid
heart disease, but this is non-specific and may often be mistaken for more common conditions
such as hypertensive or hypertrophic cardiomyopathy. Recently, it has been found that tissue
Doppler imaging could identify abnormalities in both early and late-stage cardiac amyloidosis,
affording the possibility for early diagnosis and disease-modifying intervention.[66, 67] Tissue
Doppler imaging can also be helpful in differentiating restrictive cardiomyopathy from con‐
strictive pericarditis.[68, 69] Diastolic dysfunction is the predominant pathology in cardiac
amyloidosis; the classic picture of a thick and stiff ventricle elevates diastolic filling pressures
causing restrictive hemodynamics and atrial dilatation.[70, 71] Decreased ejection fraction typi‐
cally occurs only in late-stage disease as a result of loss of myocardial contractile function
through myocyte necrosis and local interstitial amyloid infiltration;[5, 72-75] despite preserved
ejection fraction, systolic function is not normal in cardiac amyloidosis. Techniques of myocar‐
dial deformation imaging have shown that abnormal strain and strain rate imaging occur in
most cases of cardiac amyloidosis.[76-79] Amyloid cardiomyopathy seems to be associated with
a marked dissociation between short and long-axis systolic function; tissue Doppler or strain
rate imaging may show severe impairment in long-axis contraction even when the left ventricu‐
lar ejection fraction remains within the normal range.
The typical features of cardiac amyloidosis such as left ventricular wall thickening[66, 72-74,
80, 81] with myocardial hyperechogenicity,[74, 81-84] biatrial enlargement,[74, 75, 81] thick‐
ened atrial septum[81] and valve leaflets,[75, 81] as well as pericardial effusion [75, 81] are
usually seen at a more advanced stage of the disease (Figure 1). A thickened left ventricular
wall in the absence of high electrocardiographic voltages is suggestive of infiltrative cardiac
disease. Deposition in the atria is usually extensive and may cause atrial mechanical failure
and atrial standstill, i.e. atrial electro-mechanical dissociation even in patients who are in
normal sinus rhythm. Atrial involvement may also result in atrial arrhythmias; in fact, atrial
fibrillation can significantly affect the cardiac output from an already impaired ventricle.[85,
86] Heart failure can be further worsened by valvular insufficiency caused by subendocar‐
dial infiltration. [9] Rarely, pericardial involvement occurs in severe disease leading to peri‐
cardial effusion or constriction.[48] In some cases, pulmonary hypertension and cor
pulmonale may occur in patients with amyloidosis.[87] Although usually caused by con‐
comitant and frequently more severe cardiac amyloidosis with left ventricular failure,[88]
pulmonary hypertension may be the result of advanced pulmonary amyloid infiltration.[87]
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While pulmonary involvement is a harbinger of adverse outcome, it is often difficult to de‐
termine the exact extent to which pulmonary amyloid deposition contributes to symptoms
or outcome because cardiac deposition commonly coexists.[89]
 
A 
B 
C 
Figure 1. (A) Two-dimensional echocardiographic, (B) transmitral Doppler and (C) tissue Doppler images classical of
AL amyloidosis.
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Several other findings on echocardiography may have prognostic significance in cardiac
amyloidosis, such as left ventricular ejection time,[90] wall motion abnormalities,[91, 92]
dyssynchrony,[93] as well as increased right ventricular Tei index (which reflects right ven‐
tricular dysfunction).[94] Myocardial contrast echocardiography can reveal microvascular
dysfunction, and may be a useful adjunct in echocardiographic assessment for the early di‐
agnosis of cardiac amyloidosis, although it is not typically utilized in day to day practice.
[95] Transesophageal echocardiography (TEE) may be useful in characterizing atrial thrombi
and assessing left atrial appendage dysfunction,[96] a common finding in cardiac amyloido‐
sis even in the absence of atrial fibrillation (Figure 2).[96, 97] Risk factors for intracardiac
thrombosis include: AL type amyloidosis, atrial fibrillation, and diastolic dysfunction. In‐
creased right ventricular wall thickness is a marker of increased risk in intracardiac throm‐
bosis, probably due to the presence of advanced infiltrative cardiomyopathy.[14] Timely
assessment for intracardiac thrombosis in high-risk patients is important for anticoagulation
considerations.[13, 14, 98] Patients with amyloidosis should not be cardioverted without ad‐
equate anticoagulation and in some institutions, TEE imaging is routinely performed prior
to cardioversion even in the presence of adequate anticoagulation.
Figure 2. Left atrial appendage (LAA) thrombus in a patient with cardiac amyloidosis; the patient was known to be in
sinus rhythm. (With permission from Feng et al. Circulation. Nov 20 2007;116(21):2420-2426.)
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Besides its diagnostic value, echocardiography is a useful adjunct during the endomyocar‐
dial biopsy procedure. It complements, and in some institutions has replaced, fluoroscopy
as a method of bioptome guidance because of its superior resolution of the tricuspid valve
anatomy, endocardial surface, and thin right ventricular free wall and apex.[99]
5.2. Electrocardiography
Electrocardiography (ECG) provides useful and complementary information in patients
with cardiac amyloidosis. The classic findings of low voltages and pseudoinfarct patterns
(Figure 3) are common occurrences,[11, 58, 100] and both findings may occur in 25% to 50%
of patients.[43] Poor R wave progression is also often seen.[3, 101] Low voltage correlated
with the presence of a pericardial effusion but not with decreased ejection fraction.[43] The
combination of low voltage and an interventricular septum thickness >1.98 cm is very specif‐
ic for cardiac amyloidosis.[74] The finding of low voltage in a patient with echocardiograph‐
ic evidence of increased wall thickness should raise the clinical suspicion of infiltrative
cardiomyopathy, but the reverse is not necessarily true – normal voltage does not exclude
amyloidosis.[58] ECG criteria for left ventricular hypertrophy, especially limb lead ECG left
ventricular hypertrophy, however, is rarely present in patients with cardiac biopsy proven
amyloidosis.[58]
Figure 3. ECG changes classical of cardiac amyloidosis with sinus tachycardia, low voltage and pseudoinfarct patterns.
The conduction system can often be affected in cardiac amyloidosis.[11] Atrial fibrillation
and flutter are the commonest arrhythmias seen,[58] but atrioventricular and bundle branch
blocks may occur.[65] Sinus tachycardia seen in advanced cardiac amyloidosis is probably
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due to the restrictive filling leading to cardiac output adjustments based solely on heart rate;
in one study this was a marker of increased risk for intracardiac thrombosis.[14] Prolonged
QT intervals and junctional rhythms may be present. [9] Advanced ventricular arrhythmias
such as sustained ventricular tachycardia are rarely seen (although frequent PVCs, couplets
or triplets are common), which is likely due to poorly tolerance of the arrhythmia in the ad‐
vanced cardiac amyloid patients who would die suddenly from sustain VT.[58, 102] Sudden
death in severe cardiac amyloidosis is commonly attributed to electromechanical dissocia‐
tion; a pattern similar to severe cardiac diseases of other etiologies.[64]
The largest reported ECG series consists of 127 patients with AL amyloidosis and biopsy
proven cardiac involvement seen at the Mayo Clinic. The two most common abnormalities
were low voltage and a pseudoinfarct pattern, which were seen in 46 and 47 percent of cas‐
es. Other findings included first degree AV block in 21 percent, nonspecific intraventricular
conduction delay in 16 percent, second or third degree AV block in 3 percent, atrial fibrilla‐
tion or flutter in 20 percent, and ventricular tachycardia in 5 percent. ECG criteria for left
ventricular hypertrophy were present in 16 percent, but some of these patients had a history
of hypertension. The left ventricular hypertrophy criteria were limited almost exclusively to
precordial leads, sometimes with low-voltage limb leads.[58] In patients with AL amyloido‐
sis, signal-averaged ECG may demonstrate delayed myocardial activation or “late poten‐
tials”; this is an independent predictor of sudden death.[43, 100] Reduced heart rate
variability predicts mortality in the short-term in both AL and familial amyloidosis, and
probably represents autonomic dysfunction.[103, 104]
Many of the ECG findings in cardiac amyloidosis are nonspecific, and other causes of such
should be ruled out.[65] On the other hand, ECGs, especially if done serially, allows for ear‐
ly diagnosis and intervention in cardiac amyloidosis. Physicians should understand the
characteristics and symptoms of amyloidosis, and be aware of subtle changes in the ECG,
especially abnormalities that suggest disorders in the conduction system (such as prolonged
PR interval, widened QRS, atrioventricular blocks, and bundle branch blocks) or decreased
electromotive force (such as progressive R wave decrease).[105]
5.3. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (CMR) is emerging as a useful tool in the diagnosis
of  cardiac  amyloidosis.  Its  strength  lies  in  its  high  three-dimensional  spatial  resolution
and signal-to-noise ratio,  permitting reproducible measurements of cardiac chamber vol‐
umes and mass, as well as left ventricular and atrial septal wall thickness.[106] Addition‐
ally,  it  can characterize pericardial  and pleural fluid.[106] Late gadolinium enhancement
(LGE) is the cornerstone of detecting myocardial amyloid infiltrates and is seen in almost
all cases.[107] Compared with normal myocardium which has no LGE because of little ga‐
dolinium  accumulation  on  delayed  imaging,  contrast  accumulates  in  the  extracellular
space in cardiac amyloidosis which is expanded by amyloid infiltration, resulting in LGE.
[108]  The predominant  pattern of  LGE seen in cardiac amyloidosis  is  global  transmural
(Figure 4) or subendocardial; [108, 109] other patterns including focal patchy LGE and dif‐
ficulty nulling can also be seen.
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Figure 4. CMR findings of global transmural LGE classical of cardiac amyloidosis; this patient had histologically proven
AL amyloidosis. Furthermore, three intracardiac thrombi (red arrows) were detected in the left atrial appendage, right
atrial appendage and at the right atrial free wall close to tricuspid annulus.
Maceira et al [108] first studied LGE in CMR in 29 patients with cardiac amyloidosis. They
found that CMR shows a characteristic pattern of global subendocardial LGE coupled with
abnormal myocardial and blood-pool gadolinium kinetics. In 22 of these, myocardial gado‐
linium kinetics with T1 mapping was compared with that in 16 hypertensive controls. Sub‐
endocardial T1 in amyloid patients was shorter than in controls (at 4 minutes: 427±73 vs.
579±75 ms; p<0.01), and was correlated with markers of increased myocardial amyloid load
such as left ventricular mass, wall thickness, interatrial septal thickness and diastolic func‐
tion. Global subendocardial LGE was found in 20 amyloid patients (69%); these patients
had  greater  left  ventricular  mass  than  unenhanced  patients.  Histological  quantification
showed  substantial  interstitial  expansion  with  amyloid  (30.5%)  but  only  minor  fibrosis
(1.3%). Amyloid deposition was predominantly subendocardial (42%), compared with mid‐
wall (29%) and subepicardial (18%). The LGE findings agree with the transmural histologi‐
cal  distribution  of  amyloid  protein  and  the  cardiac  amyloid  load.  Using  the  difference
between the T1 of subendomyocardium and blood, a cutoff value of 191 ms at 4 minutes
had 90% sensitivity, 87% specificity and 88% of accuracy for the correct diagnosis of cardiac
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amyloidosis. There was 97% concordance in diagnosis of cardiac amyloidosis by combining
the presence of late gadolinium enhancement and an optimized T1 threshold between myo‐
cardium and blood.
Mayo investigators further evaluated the mechanism of LGE in CMR in identifying cardiac
involvement in a population of known amyloidosis patients and to investigate associations
between LGE and clinical, morphological, functional, and biochemical features.[107] Gadoli‐
nium-enhanced CMR was performed in 120 patients with amyloidosis of which 100 had AL
amyloidosis, 11 had familial amyloidosis and 9 had senile amyloidosis. Cardiac autopsy
and/or histology was available in 35 patients. The remaining 85 patients were divided into
those with and without echocardiographic evidence of cardiac amyloidosis. Abnormal LGE
was present in 34 (97%) patients with histologically proven cardiac amyloidosis. Global
transmural or subendocardial LGE (83%) was most common while suboptimal myocardial
nulling (8%) and patchy focal LGE (6%) were also observed (Figure 5). Global LGE was as‐
sociated with a higher burden of interstitial amyloid quantified from histology. LGE distri‐
bution matched the deposition pattern of interstitial amyloid at autopsy. Importantly, the
study found that LGE was present in 47% of patients without evidence of cardiac amyloido‐
sis by echocardiography. LGE presence and pattern was associated with New York Heart
Association class, ECG voltages, left ventricular mass index and thickness, right ventricular
thickness, troponin-T, and B-type natriuretic peptide levels. The global LGE patterns were
associated with the worst clinical, ECG, echocardiographic and biomarker abnormalities
compared to other types of LGE (focal or suboptimal nulling).
Figure 5. The different patterns of LGE on CMR in patients with cardiac amyloidosis. (With permission from Syed et al.
JACC Cardiovasc Imaging. 2010;3:155-164.)
CMR relaxometry is a novel approach in the diagnosis of cardiac amyloidosis, showing ele‐
vated relaxation times in patients with the disease. A T1 relaxation time cutoff value of
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≥1273 milliseconds was found to be both sensitive and specific for the diagnosis of cardiac
amyloidosis.[110]
Based on these studies, it is apparent that gadolinium-enhanced CMR is the most accurate
imaging modality to diagnose cardiac amyloidosis. LGE is common in cardiac amyloidosis
and it is due to interstitial expansion from amyloid deposition and kinetic change of gadoli‐
nium in the blood pool and myocardium/interstitia. This modality may potentially detect
early cardiac involvement in patients with amyloidosis and normal left ventricular wall
thickness.[43, 107] It also affords global assessment of the heart, eliminating the sampling er‐
ror that endomyocardial biopsy may potentially carry.[111] Furthermore, it may be useful in
detecting subclinical early cardiac involvement;[43] indeed studies have shown that even
early cardiac involvement carried a significant mortality risk, in particular cardiac mortality.
[112, 113] Serial CMR studies may have the potential to chart the progression or regression
of the disease over time after the initiation of treatment.[114] However, despite the high sen‐
sitivity and specificity of CMR in the diagnosis of cardiac amyloidosis, similar patterns,
while uncommon, have been occasionally reported in systemic sclerosis and post-heart
transplant patients. The autopsy study by Syed et al suggests that rarely, gadolinium-en‐
hanced CMR may be falsely negative because the amyloid infiltrate is mild.[107]
CMR may be a reasonable adjuvant or even an alternative to endomyocardial biopsy, espe‐
cially in patients with a tissue diagnosis from a remote site and who are high-risk for inva‐
sive investigation. However, it is important to notice that the diagnosis of cardiac
amyloidosis is confirmed by demonstrating amyloid deposits on endomyocardial biopsy.
Cardiac amyloidosis may be presumably, but not conclusively, established in patients with
appropriate cardiac imaging findings with demonstration of amyloid deposits on histologi‐
cal examination of a biopsy from other tissues (e.g., abdominal fat pad, rectum, or kidney).
There are several limitations in the use of this modality. Firstly, it is incompatible with pa‐
tients with implanted devices such as pacemakers or implantable cardioverter-defibrillators.
Nevertheless, pacemakers compatible with magnetic resonance imaging were recently ap‐
proved by the United States Food and Drug Administration for clinical use in the 1.5 tesla
magnetic resonance imaging scanner. Secondly, gadolinium contrast administration is con‐
traindicated in patients whose creatinine clearance is less than 30 mL/minute given the risk
of nephrogenic systemic fibrosis.[115] Many patients with cardiac amyloidosis have indica‐
tions for heart failure device therapy (e.g. pacemakers, implantable cardioverter-defibrilla‐
tors) as well as renal impairment as a result of amyloid deposition in the kidneys, both of
which may preclude them from undergoing CMR.
5.4. Nuclear scintigraphy
Several single-photon emission computed tomography tracers have been evaluated in the
diagnosis of cardiac amyloidosis.[116] There is evidence that [123]I-metaiodobenzylguani‐
dine may be an indirect measure of cardiac amyloid deposition. The finding of intense up‐
take in the heart on [99]mTc-pyrophosphate scintigraphy, which was indicative of cardiac
amyloidosis, was insufficiently sensitive to warrant routine use in the diagnosis of the dis‐
ease. While not routinely performed for diagnosing cardiac amyloidosis given its variable
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sensitivity, a new technique, [99]mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintig‐
raphy, may be able to differentiate familial transthyretin-associated amyloidosis from AL
amyloidosis, a clinically-relevant distinction; however, further study into this new technique
is needed.[117]
5.5. Fat aspirate and endomyocardial biopsy for tissue diagnosis
Even with current imaging technology, amyloidosis remains a histological diagnosis (Figure
6). The presence of serum or urine monoclonal paraprotein is suggestive of AL amyloidosis,
but on its own does not firmly establish the diagnosis because low serum concentrations of a
monoclonal protein (possibly from an unrelated monoclonal gammopathy of undetermined
significance) can incorrectly suggest AL amyloid in some familial cardiac amyloidosis con‐
firmed later by cardiac biopsy.[118] For the diagnosis of systemic disease, less invasive tis‐
sue sampling methods are available.[9] Biopsies may be taken from the abdominal
subcutaneous fat, with sensitivities of >80% for the latter in AL.[119-121]. Abdominal subcu‐
taneous fat aspiration is easily obtained with minimal risk and is now preferred over rectal
biopsy. Endomyocardial biopsy should be considered if the diagnosis of amyloidosis cannot
be made with noninvasive techniques and the suspicion of cardiac amyloidosis remains
high, or in cases of isolated cardiac amyloidosis, for example in the isoleucine 122 form of
familial amyloidosis and senile systemic amyloidosis.[9] The sensitivity of four endomyocar‐
dial biopsy samples for the disease is nearly 100%.[111] Mass spectrometry of the tissue bi‐
opsy is used to determine the type of amyloidosis.
Figure 6. Histologic findings classical of cardiac amyloidosis. Hematoxylin and eosin staining of an amyloid-infiltrated
left ventricular myocardium is shown here. The amyloid protein stained an amorphic light pink color (arrows).
Amyloidosis46
5.6. Biochemical markers and prognostication
Cardiac  biomarkers  may  be  elevated  in  cardiac  amyloidosis,  often  disproportionate  to
the  clinical  presentation.[122]  Amyloid-induced  myonecrosis  and  small  vessel  ischemia
causes raised cardiac troponins,[123] while diastolic dysfunction and upregulation of na‐
triuretic  peptide  genes  in  diseased  ventricles  result  in  elevated  B-type  natriuretic  pep‐
tide levels.[124]
Cardiac troponins and N-terminal-pro-B-type natriuretic  peptide are important  prognos‐
tic  indicators  in  cardiac  amyloidosis,  and also  allow for  monitoring  progression  of  dis‐
ease or  efficacy of  therapy.[43,  77,  125-127]  One study showed a significantly decreased
median survival in patients with troponin elevation; this may even predict survival bet‐
ter  than  symptomatic  congestive  heart  failure  and  two-dimensional  echocardiographic
findings.[128]  A  30%  decrease  in  N-terminal-pro-B-type  natriuretic  peptide  after  effec‐
tive  chemotherapy  correlates  with  increased  event-free  survival  even  without  objective
echocardiographic findings.[129]  A combination of  high-sensitivity cardiac troponin T at
presentation  and  N-terminal-pro-B-type  natriuretic  peptide  changes  after  chemotherapy
had superior  predictive value for  survival.[130]  Serum uric  acid is  a  novel  independent
prognostic  factor in AL amyloidosis.  The median overall  survival  was lower in patients
with uric  acid levels  ≥8  mg/dL.[131]  A combination of  uric  acid,  troponin T and N-ter‐
minal-pro-B-type  natriuretic  peptide  provides  a  strong  predictive  model  for  early  mor‐
tality.[132]
The serum immunoglobulin free light chain assay enables quantification of  aberrant cir‐
culating  amyloidogenic  fibril  protein  precursors.[129]  It  enables  serial  monitoring  of
amyloidogenic  light  chain production during chemotherapy.[133]  A fall  in  aberrant  free
light  chain  production  by  half  following  chemotherapy  was  associated  with  reductions
in  N-terminal-pro-B-type  natriuretic  peptide  but  not  in  left  ventricular  wall  thickness,
and  was  associated  with  clinical  improvement.[129]  Further  highly  reproducible  and
quantifiable  imaging  studies  such  as  CMR  may  assist  in  defining  associations  between
cardiac function and alterations in light chain load.[43]
6. Management of cardiac amyloidosis
Although the management of  cardiac amyloidosis  is  challenging,  evolution of  treatment
options have improved prognosis. It  is essential to determine the type of amyloidosis to
guide  treatment.[43]  In  general,  the  management  aims  can  be  broadly  divided  into  the
general  supportive  care  of  cardiac  and  extracardiac  manifestations  of  the  disease,  as
well  as  type-specific  targeted therapy.[5,  43]  Table  2  shows a  general  algorithm for  the
investigation and management of cardiac amyloidosis.
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Step 1 – Identification of clinical scenarios suspicious for cardiac amyloidosis
Any one of the features below could trigger clinical suspicion – NOT all are required
 •Dyspnea with exertion or heart failure of unknown etiology, often with thickening of the LV and/or RV walls, 
especially if associated with low voltages on ECG
 •Unexplained fatigue and weight loss
 •Associated hepatomegaly, nephrotic-range proteinuria, peripheral or autonomic neuropathy, carpal tunnel 
syndrome, family history of amyloidosis
 •Periorbital purpura (rare but almost pathognomonic) and macroglossia
Step 2 – Cardiac diagnostic assessment
 •Detailed echocardiographic examination including diastolic function analysis, tissue Doppler, strain imaging, 
assessment of RV wall thickness
 •Cardiac MRI with late gadolinium enhancement
 •Cardiac biomarkers: troponin T and NT-proBNP
Step 3 – Further evaluation for the diagnosis of amyloidosis
 •Screening biopsy of abdominal subcutaneous fat aspirate or rectal mucosa with Congo red staining
 •Screen serum and urine for monoclonal protein, serum free light chain assay
 •If clinical suspicion remains high despite the above being negative, consider endomyocardial biopsy (or other 
involved organ) with Congo red staining
Step 4 – Determination of the amyloid fibril type (if the diagnosis of amyloidosis is made)
Tissue diagnosis and correct typing of amyloid is critical
 •Mass spectrometry based proteomic analysis of tissue containing amyloid to determine specific type of amyloid 
protein
Step 5 – Do specific testing based on type of amyloidosis
 •Bone marrow aspirate and biopsy if diagnosis is AL amyloidosis or myeloma with associated amyloidosis
 •For TTR-related amyloidosis, genetic testing to distinguish between age-related and hereditary variant TTR types
 •For other hereditary amyloidoses, appropriate genetic testing for family counseling
Step 6 – Type-specific treatment
 •AL amyloidosis: quantify light chains (as baseline for follow-up), exclude concomitant myeloma, troponin and NT-
proBNP measurements for staging (if not done), supportive therapy, and determine which chemotherapy (including 
possible autologous stem cell transplant) and/or whether, sequential cardiac and autologous stem cell transplant is 
appropriate
 •Familial amyloidosis: supportive therapy; assess for liver transplant with or without heart transplant
 •Reactive amyloidosis: treating the underlying chronic inflammatory state and anti-cytokines therapy (IL-6, TNFα)
 •Senile systemic amyloidosis: supportive therapy and possibly tafamidis in the future
AL, immunoglobulin light chain; ECG, electrocardiogram; LV, left ventricular; NT-proBNP, N-terminal prohormone
brain natriuretic peptide; RV, right ventricular; TTR, transthyretin
Table 2. Evaluating a patient with suspected cardiac amyloidosis.
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6.1. General supportive care
The traditional teaching that amyloidosis with cardiac involvement is universally fatal has
dramatically changed in the last decade, largely due to chemotherapy and stem cell trans‐
plant therapies. However, important supportive care measures are necessary to achieve
these outcomes.
Cardiac  manifestations  of  amyloidosis  primarily  include  heart  failure  and  cardiac  ar‐
rhythmias. The mainstay of heart failure treatment in cardiac amyloidosis is diuresis; pa‐
tients  with  hypoalbuminemia  due  to  concomitant  nephrotic  syndrome  require  high
doses. It is essential to monitor fluid balance meticulously with daily weighing and diu‐
retic dose adjustment.[5, 43] For a variety of reasons, beta-blockers, [9] renin-angiotensin
system  inhibitors,[5,  43]  digoxin  [134,  135]  and  calcium  channel  blockers[136]-[138]
should  be  avoided  where  possible.  In  markedly  impaired  diastolic  filling  and  reduced
stroke volume, tachycardia is a compensatory mechanism that maintains cardiac output.
Consequently,  high  doses  of  beta-adrenergic  receptor  blocking  agents  are  often  poorly
tolerated.  Calcium channel  blockers  and digitalis  are  considered  contraindicated  in  car‐
diac amyloid disease due to potential binding of amyloid fibrils and potentiation of drug
toxicity. Evidence for the use of vasodilator or inotropic agents in cardiac amyloidosis is
lacking,  but  renal-dose  dopamine  may  be  helpful  in  the  treatment  of  anasarca  if  renal
function is  unimpaired.[5]  Recurrent  large pleural  effusions may represent  pleural  amy‐
loid  and  may  require  thoracentesis  and  occasionally,  pleurodesis.[139]  Placement  of  a
pleural  catheter can helpful  for palliation of  recurrent pleural  effusions.  Anticoagulation
should be administered for standard indications such as intracardiac thrombus and atrial
fibrillation, and an embolic event even in the absence of atrial fibrillation should trigger
a  search  for  intracardiac  thrombosis.[14,  43,  97,  140]  Appropriate  selection  of  patients
suitable for thromboembolic prophylaxis is difficult given the high anticoagulation-associ‐
ated bleeding risk due to vascular fragility and coagulopathy in amyloidosis.
Patient with cardiac amyloidosis are predisposed to many different types of arrhythmias,
[57, 58] most commonly atrial fibrillation.[58] Given the atrial dilation from increased ven‐
tricular end-diastolic pressures as well as atrial amyloid infiltration, restoration of sinus
rhythm is challenging and frequently unsuccessful in the long term.[14] It is reasonable,
however, to attempt sinus rhythm restoration with DC cardioversion in highly symptomatic
and medication refractory cases, provided no atrial thrombus is present by TEE. Atrial fibril‐
lation recurs in most patients, and as such a rate-control and anticoagulation strategy is war‐
ranted in most circumstances. Patients with AL amyloidosis with concomitant AF are at an
extremely high risk of thromboembolism, and the thromboembolic risk in transthyretin-re‐
lated amyloidosis is also elevated above that of non-amyloid AF patients. Proper anticoagu‐
lation therapy reduces thromboembolic risk.[14] Amiodarone can be useful as both a rate
controlling and rhythm maintaining agent. Amiodarone is presumed safe in cardiac amyloi‐
dosis although systemic study is lacking. Patients must be monitored for the known toxici‐
ties, and the drug should be avoided in the presence of significant conduction disease (e.g.,
left bundle branch block) without pacemaker placement. Dronedarone as well as many oth‐
er antiarrhythmic medications (typically of classes IA, IC and III) have not been well studied
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in cardiac amyloidosis. However, based on studies in patients with structural heart disease
and heart failure, they should be considered as contraindicated in advanced amyloid pa‐
tients at this time. Sudden death is often due to electromechanical dissociation; however,
ventricular tachyarrhythmias are not infrequent.[102] The role of implantable cardioverter-
defibrillator for primary prevention of sudden cardiac death in cardiac amyloid remains un‐
clear and controversial. Strategies to reduce the elevated defibrillation thresholds in cardiac
amyloidosis such as a subcutaneous array lead system may improve the efficacy of implant‐
able cardioverter-defibrillator therapy.[141] The standard indications for pacing generally
apply to cardiac amyloidosis,[142] but the threshold to introduce pacing is often lower in
view of the propensity for the concomitant autonomic neuropathy and hypoalbuminemia to
worsen any preexisting amyloidosis-related hemodynamic compromise.[43] Dual-chamber
pacing may be particularly useful for optimizing the atrial filling component in this restric‐
tive cardiomyopathy.[43] However, there is no evidence that the symptomatic improvement
from pacing translates into increased survival.[143] The generally accepted indications for
cardiac resynchronization therapy apply in cardiac amyloidosis.[144] There are currently no
prospective randomized controlled trials evaluating the use of continuous intra-axial cardiac
flow pumps and left ventricular assist devices, but one patient received the former in a feasi‐
bility study with subsequent symptom relief.[145]
6.2. Targeting the underlying amyloid pathology
This is an area of management that is specific to the type of amyloidosis, but the general
aim is to decrease the formation new amyloid proteins and possibly facilitate the regres‐
sion of existing deposits.[5,  43] Recent advancements in both our ability to diagnose the
type  of  amyloidosis  and  the  treatment  options  for  the  various  types  have  greatly  im‐
proved outcome.[43]
AL amyloidosis. The mainstay of treatment in this type of amyloidosis is targeting the patho‐
genic light chain-producing clonal plasma cells with chemotherapy.[146-152] This minimiz‐
es amyloid production (potentially reversing the disease process), preserves organ function
and enhances survival.[153, 154] Indeed, immunoassays for free light chains are useful in
monitoring the disease process and responses to treatment, and halving the aberrant mono‐
clonal light chain on a sustained basis improves survival.[154] Reducing the circulating
amyloidogenic precursor may result in some improvement in cardiac function even as the
cardiac amyloid load found on echocardiography remains fairly constant.[129] These find‐
ings supports the direct toxic role of the aberrant monoclonal light chain on myocardial
function that was shown in an animal model.[47] Moreover, similar findings were observed
in other organs. For example, serial kidney biopsies in patients with AL amyloidosis before
and after clinically successful treatments reveal unchanging amyloid burden despite signifi‐
cant improvement in proteinuria.[155, 156]
For patients who are fit for chemotherapy, several treatment regimens exist. The historic
regimen of melphalan and prednisolone had responses that were few and much delayed;
[157] more rapid responses are seen with intermediate-intensity regimens like melphalan
and dexamethasone.[43] High-dose chemotherapy with autologous stem cell replacement
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has been attempted, but significant cardiac involvement precludes it given the high peri‐
treatment mortality.[5, 153] Many patients are diagnosed at a stage at which such an ag‐
gressive  therapeutic  modality  is  too  toxic;  early  studies  in  which  patients  were  not
carefully  selected for  high-dose chemotherapy with autologous stem cell  transplant  had
transplant-related  mortality  of  nearly  50%.[5,  158]  The  presence  of  symptomatic  and
structural  features  of  cardiac  amyloidosis  strongly  predicts  poor  outcomes  from autolo‐
gous stem cell replacement,[159, 160] and the presence of clinical findings consistent with
advanced  disease,  multiorgan  involvement  and  poor  functional  status  should  preclude
autologous  stem  cell  therapy.[160,  161]  Newer  and  investigational  approaches  include
thalidomide or  lenolidamide mono-  or  combination therapy,[151,  162,  163]  rituximab to
target  CD20-positive  plasma  cell  clones,[164]  and  the  proteasome  inhibitor  bortezomib.
[165-167] Heart transplantation is infrequently performed due to concerns about extracar‐
diac  disease  progression  as  well  as  amyloid  deposition  in  the  transplant  heart.  Indeed
heart  transplant  survival  rates  were  lower  in  cardiac  amyloidosis  compared  with  other
indications.[168, 169] Sequential heart and stem cell transplant is promising in young pa‐
tients with cardiac failure and preserved extracardiac organ function,  with a 1-year sur‐
vival of between 75% and 83%.[170-173] While there are several predictors of prognosis,
it is at present difficult to select patients for the appropriate treatment regimen.[5, 43] In
some  patients  high-intensity  regimens  may  be  excessive,  but  in  others  the  disease  re‐
mains  refractory  even  to  the  most  intense  of  regimens.[43]  Therefore  highly-individual‐
ized management of cardiac amyloidosis is essential.[43]
Familial amyloidosis. Because plasma transthyretin is mainly synthesized in the liver, defini‐
tive treatment for familial amyloidosis requires liver transplantation to arrest the synthesis
of amyloidogenic proteins, as well as transplantation of failed organs.[174] Outcomes are
generally favorable in young and fit patients with the methionine 30 mutation. However, in
older patients of the non-methionine 30 variants, paradoxical acceleration of disease pro‐
gression has been reported, necessitating combined heart and liver transplants.[175-177]
There is some evidence that transthyretin can be stabilized by certain nonsteroidal agents
like diflunisal; clinical trials are necessary to investigate their efficacy in preventing disease
progression.[178] These agents, however, may precipitate or aggravate congestive heart fail‐
ure by fluid retention, and other agents are actively being sought.[179] One promising thera‐
peutic candidate is tafamidis, a small-molecule transthyretin stabilizer which prevents
transthyretin from forming amyloid fibrils. Tafamidis has demonstrated efficacy for the
treatment of ATTR polyneuropathy, and has therefore been granted orphan drug status in
the United States. Tafamidis is currently undergoing Phase II trials for the treatment of
ATTR cardiomyopathy.[180]
Reactive amyloidosis. Definitive treatment involves treating the underlying inflammatory
process and decreasing the serum amyloid A concentration, improving survival.[181] In‐
flammatory syndromes such as rheumatoid arthritis, Crohn’s disease, seronegative spondy‐
loarthropathies, and several periodic fever syndromes can be effectively treated with tumor
necrosis factor and interleukin-1 inhibitors.[182] Familial Mediterranean fever can be treated
with colchicine,[183] while excision of interleukin-6-secreting masses is an effective treat‐
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ment for Castleman’s disease.[184] A randomized controlled trial showed that eprodisate
slows the decline of renal function in reactive amyloidosis, [185] and may have possible ap‐
plicability to other types of amyloidosis.[186]
Currently, there is no known treatment that specifically targets senile amyloid, but research
into this field is quickly evolving. Investigational approaches undergoing intensive research
include targeted therapies that stabilize the soluble form of amyloidogenic proteins and re‐
verse preexisting deposits. A new therapy based on epigallocatechin gallate, a compound
that binds to denatured protein thereby inhibiting the formation of insoluble amyloid, has
been proposed.[65] These potential new therapies offer exciting prospects for improvements
in treatment.[43, 65]
7. Conclusion
Amyloidosis describes a heterogeneous group of several uncommon diseases by aberrant
protein deposition in tissues throughout the body. Cardiac amyloidosis refers to clinically
significant cardiac involvement, causing restrictive cardiomyopathy and its resultant effects,
the most severe being congestive heart failure and arrhythmias. It is often underdiagnosed.
However, recent advances in imaging have allowed us to accurately diagnose the condition
and better characterize the degree of cardiac involvement. Cardiac biomarkers are useful in
monitoring disease progression and response to therapy. The treatment of cardiac amyloi‐
dosis is rapidly evolving, and encompasses general supportive care of cardiac and extracar‐
diac manifestations of the disease, and in addition, the management of the underlying
amyloid disease process. Importance must be attached to early diagnosis of the disease, par‐
ticularly in AL amyloidosis, because patients diagnosed late are often too ill to undergo dis‐
ease-modifying chemotherapy. Novel therapies are actively being investigated and may
present exciting new frontiers in the treatment of the disease.
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